Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for ICP-022 in relapsed/refractory mantle cell lymphoma across Phase 1 and Phase 2 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• ICP-022

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN